This clinical trial is focused on studying Acute Ischemic Stroke (AIS), a condition where blood flow to a part of the brain is blocked, leading to potential brain damage. The study will evaluate a treatment called LT3001 Drug Product, which is administered as a solution through an intravenous infusion. This means the medication is given directly into a vein. The trial will also use a placebo for comparison purposes.

The purpose of the study is to determine the safety of multiple doses of the LT3001 Drug Product in individuals who have experienced an Acute Ischemic Stroke. Participants will receive either the drug or a placebo, and their health will be monitored to assess any side effects or adverse reactions. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual drug or the placebo, to ensure unbiased results.

Participants in the study will be monitored for a period of time after receiving the treatment to observe any potential side effects. The main focus will be on identifying any adverse events that may be related to the treatment within 90 days of the first administration. This trial aims to provide valuable information on the safety and potential benefits of the LT3001 Drug Product for those affected by Acute Ischemic Stroke.